These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
133 related articles for article (PubMed ID: 16684603)
1. 136th ENMC International Workshop: Charcot-Marie-Tooth disease type 1A (CMT1A)8-10 April 2005, Naarden, The Netherlands. Reilly MM; de Jonghe P; Pareyson D Neuromuscul Disord; 2006 Jun; 16(6):396-402. PubMed ID: 16684603 [No Abstract] [Full Text] [Related]
2. [Ascorbic Acid and Charcot-Marie-Tooth Disease]. Noto Y Brain Nerve; 2015 Oct; 67(10):1241-6. PubMed ID: 26450076 [TBL] [Abstract][Full Text] [Related]
3. Effect of ascorbic acid in patients with Charcot-Marie-Tooth disease type 1A: a multicentre, randomised, double-blind, placebo-controlled trial. Micallef J; Attarian S; Dubourg O; Gonnaud PM; Hogrel JY; Stojkovic T; Bernard R; Jouve E; Pitel S; Vacherot F; Remec JF; Jomir L; Azabou E; Al-Moussawi M; Lefebvre MN; Attolini L; Yaici S; Tanesse D; Fontes M; Pouget J; Blin O Lancet Neurol; 2009 Dec; 8(12):1103-10. PubMed ID: 19818690 [TBL] [Abstract][Full Text] [Related]
4. Charcot-Marie-Tooth disease type 1A: is ascorbic acid effective? Pareyson D; Solari A Lancet Neurol; 2009 Dec; 8(12):1075-7. PubMed ID: 19818689 [No Abstract] [Full Text] [Related]
5. Ascorbic acid for Charcot-Marie-Tooth disease type 1A in children: a randomised, double-blind, placebo-controlled, safety and efficacy trial. Burns J; Ouvrier RA; Yiu EM; Joseph PD; Kornberg AJ; Fahey MC; Ryan MM Lancet Neurol; 2009 Jun; 8(6):537-44. PubMed ID: 19427269 [TBL] [Abstract][Full Text] [Related]
6. Poor tolerability of high dose ascorbic acid in a population of genetically confirmed adult Charcot-Marie-Tooth 1A patients. Toth C Acta Neurol Scand; 2009 Aug; 120(2):134-8. PubMed ID: 19154534 [TBL] [Abstract][Full Text] [Related]
7. 221st ENMC International Workshop:: Foot Surgery in Charcot-Marie-Tooth disease. 10-12 June 2016, Naarden, The Netherlands. Reilly MM; Pareyson D; Burns J; Laurá M; Shy ME; Singh D; Neuromuscul Disord; 2017 Dec; 27(12):1138-1142. PubMed ID: 29074294 [No Abstract] [Full Text] [Related]
8. Oral high dose ascorbic acid treatment for one year in young CMT1A patients: a randomised, double-blind, placebo-controlled phase II trial. Verhamme C; de Haan RJ; Vermeulen M; Baas F; de Visser M; van Schaik IN BMC Med; 2009 Nov; 7():70. PubMed ID: 19909499 [TBL] [Abstract][Full Text] [Related]
9. Ascorbic acid for treatment in CMT1A: what's next? de Visser M; Verhamme C Lancet Neurol; 2011 Apr; 10(4):291-3. PubMed ID: 21393064 [No Abstract] [Full Text] [Related]
10. Ascorbic acid for treatment of CMT1A: the jury is still out. Shy M Lancet Neurol; 2009 Jun; 8(6):505-7. PubMed ID: 19427270 [No Abstract] [Full Text] [Related]
11. [Ascorbic acid: a first generation drug for Charcot-Marie-Tooth disease]. Fontès M Med Sci (Paris); 2004 Oct; 20(10):843-4. PubMed ID: 15461953 [No Abstract] [Full Text] [Related]
12. 2nd Workshop of the European CMT Consortium: 53rd ENMC International Workshop on Classification and Diagnostic Guidelines for Charcot-Marie-Tooth Type 2 (CMT2-HMSN II) and Distal Hereditary Motor Neuropathy (distal HMN-Spinal CMT) 26-28 September 1997, Naarden, The Netherlands. Neuromuscul Disord; 1998 Aug; 8(6):426-31. PubMed ID: 9713862 [No Abstract] [Full Text] [Related]
13. Ascorbic acid treatment corrects the phenotype of a mouse model of Charcot-Marie-Tooth disease. Passage E; Norreel JC; Noack-Fraissignes P; Sanguedolce V; Pizant J; Thirion X; Robaglia-Schlupp A; Pellissier JF; Fontés M Nat Med; 2004 Apr; 10(4):396-401. PubMed ID: 15034573 [TBL] [Abstract][Full Text] [Related]
14. A multicenter, randomized, double-blind, placebo-controlled trial of long-term ascorbic acid treatment in Charcot-Marie-Tooth disease type 1A (CMT-TRIAAL): the study protocol [EudraCT no.: 2006-000032-27]. Pareyson D; Schenone A; Fabrizi GM; Santoro L; Padua L; Quattrone A; Vita G; Gemignani F; Visioli F; Solari A; Pharmacol Res; 2006 Dec; 54(6):436-41. PubMed ID: 17029975 [TBL] [Abstract][Full Text] [Related]
15. A Rasch Analysis of the Charcot-Marie-Tooth Neuropathy Score (CMTNS) in a Cohort of Charcot-Marie-Tooth Type 1A Patients. Wang W; Guedj M; Bertrand V; Foucquier J; Jouve E; Commenges D; Proust-Lima C; Murphy NP; Blin O; Magy L; Cohen D; Attarian S PLoS One; 2017; 12(1):e0169878. PubMed ID: 28095456 [TBL] [Abstract][Full Text] [Related]
16. Whither hope for pharmacological treatment of Charcot-Marie-Tooth disease type 1A? Patel PI; Pleasure D JAMA Neurol; 2013 Aug; 70(8):969-71. PubMed ID: 23797977 [No Abstract] [Full Text] [Related]
17. 168th ENMC International Workshop: outcome measures and clinical trials in Charcot-Marie-Tooth disease (CMT). Reilly MM; Shy ME; Muntoni F; Pareyson D Neuromuscul Disord; 2010 Dec; 20(12):839-46. PubMed ID: 20850975 [No Abstract] [Full Text] [Related]
18. 118th ENMC International Workshop on Advances in Myotubular Myopathy. 26-28 September 2003, Naarden, The Netherlands. (5th Workshop of the International Consortium on Myotubular Myopathy). Bertini E; Biancalana V; Bolino A; Buj Bello A; Clague M; Guicheney P; Jungbluth H; Kress W; Musaro' A; Nandurkar H; Pirola L; Romero N; Senderek J; Suter U; Sewry C; Tronchere H; Wallgren-Pettersson C; Wishart MJ; Laporte J Neuromuscul Disord; 2004 Jun; 14(6):387-96. PubMed ID: 15145343 [No Abstract] [Full Text] [Related]
19. Quality of life in children with CMT type 1A. Ramchandren S; Shy ME; Finkel RS Lancet Neurol; 2009 Oct; 8(10):880-1; author reply 881. PubMed ID: 19747650 [No Abstract] [Full Text] [Related]
20. Ascorbic acid and sodium-dependent vitamin C transporters in the peripheral nervous system: from basic science to clinical trials. Gess B; Röhr D; Young P Antioxid Redox Signal; 2013 Dec; 19(17):2105-14. PubMed ID: 23642070 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]